Effects of palmitoylethanolamide in clinical high-risk for psychosis: A nonrandomized open-label trial.

ABSTRACT: Clinical high-risk (CHR) for psychosis state still lacks effective and safe treatments. Recent evidence supports the anti-neuroinflammatory properties of fatty acid palmitoylethanolamide (PEA) dietary supplementation across the psychosis spectrum. Sixteen subjects at CHR for psychosis with attenuated psychotic symptoms (APS) enrolled in a 12-week, open-label, nonrandomized, single-arm clinical trial of ultramicronized-PEA (um-PEA, 600 mg/day). Biobehavioral assessments were conducted at baseline, 4 weeks, and 12 weeks, particularly using the Comprehensive Assessment of At-Risk Mental States (CAARMS) and quantifying changes in peripheral neuroimmune biomarkers. Linear mixed-effects models showed significant reductions in CAARMS total APS (Δ_12-weeks = -3.8 units, -30.0 %) and Unus

SUBMITTER: Bortoletto R 

PROVIDER: S-EPMC12689190 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature